Lyell Immunopharma (LYEL) Assets (2020 - 2026)
Lyell Immunopharma (LYEL) posted Assets of $350.6 million for Q1 2026, up 3.11% sequentially from $340.1 million in Q4 2025, and down 18.42% YoY from $429.8 million in Q1 2025.
Lyell Immunopharma (LYEL) Assets (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Assets for 7 years, with the latest figure at $350.6 million in Q1 2026.
- Quarterly Assets fell 18.42% year-over-year to $350.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $350.6 million (down 18.42% YoY) and the FY2025 annual result came in at $340.1 million, down 30.72% from the prior year.
- Assets grew to $350.6 million in Q1 2026 per LYEL's latest filing, from $340.1 million in the prior quarter.
- Over five years, Assets peaked at $1.1 billion in Q1 2022 and troughed at $340.1 million in Q4 2025.
- A 5-year average of $684.8 million and a median of $694.2 million in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2025: Assets retreated 16.84% in 2022, then slumped 41.08% in 2025.
- Over 5 years, Assets stood at $937.6 million in 2022, then declined by 20.0% to $750.0 million in 2023, then sank by 34.55% to $490.9 million in 2024, then slumped by 30.72% to $340.1 million in 2025, then rose by 3.11% to $350.6 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $350.6 million, $340.1 million, and $408.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | 311.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 311.15 Mn |
| Mar 31, 2026 | 350.63 Mn |
| Dec 31, 2025 | 340.05 Mn |
| Sep 30, 2025 | 407.97 Mn |
| Jun 30, 2025 | 385.45 Mn |
| Mar 31, 2025 | 429.80 Mn |
| Dec 31, 2024 | 490.86 Mn |
| Sep 30, 2024 | 619.22 Mn |
| Jun 30, 2024 | 654.14 Mn |
| Mar 31, 2024 | 694.22 Mn |
| Dec 31, 2023 | 750.03 Mn |
| Sep 30, 2023 | 794.99 Mn |
| Jun 30, 2023 | 835.35 Mn |
| Mar 31, 2023 | 880.45 Mn |
| Dec 31, 2022 | 937.56 Mn |
| Sep 30, 2022 | 977.27 Mn |
| Jun 30, 2022 | 1.02 Bn |
| Mar 31, 2022 | 1.07 Bn |
| Dec 31, 2021 | 1.13 Bn |
| Sep 30, 2021 | 1.20 Bn |